Journal
CANCER CELL
Volume 21, Issue 4, Pages 451-453Publisher
CELL PRESS
DOI: 10.1016/j.ccr.2012.03.027
Keywords
-
Categories
Funding
- NCI NIH HHS [R01 CA155328] Funding Source: Medline
- NHLBI NIH HHS [R01 HL087188] Funding Source: Medline
Ask authors/readers for more resources
KDM1A/LSD1, a histone H3K4/K9 demethylase and epigenetic regulator with roles in both gene activation and repression, has increased expression in multiple cancer types. Harris et al., in this issue of Cancer Cell, and Schenk et al. show that KDM1A may be a viable therapeutic target in treating AML.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
